Compare BIO-TECHNE Corp (TECH) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Weibo Corp — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Weibo Corp trades at $6.46 (market cap $1.57B). The key difference: BIO-TECHNE Corp is far larger — about 7.2× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.41%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Weibo Corp for 102 Days on average.
| TECH | WB | |
|---|---|---|
Market Cap | $11.37B | $1.57B |
Volume | 3,153,511 | 947,144 |
Sector | Health | Media |
52-Week High | $72.61 | $12.37 |
52-Week Low | $43.31 | $6.33 |
Typical Hold Time | 63 Days | 102 Days |
Enterprise Value | $11.40B | $799.15M |
Dividend Yield | 0.44% | 9.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Weibo (WB) trades at $6.44, down 0.77% on the day, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics with a P/E of 5.36 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins and 17.78% net income margin. Recent Q2 2026 earnings beat expectations with $0.38 EPS versus $0.36 expected, though Q1 and Q4 2025 missed estimates. Cash flow trends show volatility, with 2024 net cash flow negative $694 million but improving to positive $408 million in 2025.
Weibo presents a deep-value opportunity with compelling valuation multiples, though growth concerns persist amid declining user metrics and advertising revenue challenges. Analyst sentiment remains mixed with 41% buy ratings versus 45% hold, reflecting uncertainty about the company's ability to maintain relevance against intensifying competition. Key risks include stagnating user growth and advertising market pressures, while the current price offers margin of safety for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
